Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial
Authors' conclusion
This study identified distinct lipid signatures associated with Empagliflozin treatment after both one and twelve weeks, respectively, with five lipids overlapping between signatures and three with consistent directions, revealing that some of the beneficial effects of Empagliflozin could be through lipid modulation. Notably, Empagliflozin-modulated lipids associated with changes in clinical traits and lipid-specific profiles among clinical subgroups were observed. However, challenges remain in establishing direct associations between individual lipids and clinical outcomes. Future research integrating lipidomics data with other omics datasets could provide a more comprehensive understanding of the identified lipid signatures and their potential roles in health and diseases.
Study context
- Population
- Patients with T2D and heart failure (HF) from the EmDia trial, University Medical Center of Mainz
- Participants
- 144 patients
- Comparison
- Empagliflozin treatment, lipid signatures after 1 and 12 weeks
Methodological detailsdouble-blind, single-centre
- Double-blind
- Single-centre
Primary result
As reported in the abstract
Lipid signature after 1 week: lipids from lysophosphatidylcholine (LPC), phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM) and triacylglycerol (TG) groups
37 lipids
Lipid signature after 12 weeks: lipids from the same five groups plus ceramides
24 lipids
Lipids altered at both time points with consistent directional trends
3 of 5
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →